WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer

[1]  N. Hastie,et al.  WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer , 2018, British Journal of Cancer.

[2]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[3]  E. Crawford,et al.  Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas , 2017, Modern Pathology.

[4]  Stuart Aitken,et al.  WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel , 2017, Scientific Reports.

[5]  P. Fasching,et al.  Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study , 2017, Breast Cancer Research and Treatment.

[6]  D. Scheinberg,et al.  Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen , 2016, Leukemia.

[7]  Fan Zhang,et al.  Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis , 2015, Scientific Reports.

[8]  Rodney J Scott,et al.  Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value , 2015, Nature Communications.

[9]  E. Gilson,et al.  The Wilms’ tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression , 2014, Nature Communications.

[10]  P. Kuppen,et al.  How does genome sequencing impact surgery? , 2014, Nature Reviews Clinical Oncology.

[11]  Sarah E. Seton-Rogers.  Tumour heterogeneity: A cooperative tumour cell community , 2014, Nature Reviews Cancer.

[12]  Y. Takeda,et al.  Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer , 2014, Journal of immunotherapy.

[13]  S. Y. Kim,et al.  Prognostic significance of RSPO1, WNT1, P16, WT1, and SDC1 expressions in invasive ductal carcinoma of the breast , 2013, World Journal of Surgical Oncology.

[14]  Jason I. Herschkowitz,et al.  Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts , 2013, Genome Biology.

[15]  W. Coleman,et al.  Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. , 2013, The American journal of pathology.

[16]  M. Piccart,et al.  Emerging targeted agents in metastatic breast cancer , 2013, Nature Reviews Clinical Oncology.

[17]  J. Sakamoto,et al.  WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial , 2013, Journal of Cancer Research and Clinical Oncology.

[18]  G. Fraizer,et al.  The Wilms’ tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells , 2013, Molecular Cancer.

[19]  N. Hastie,et al.  The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis. , 2012, Trends in genetics : TIG.

[20]  Li-shan Wang,et al.  High Wilms' tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer. , 2012, Oncology reports.

[21]  I. Jatoi,et al.  The global breast cancer burden. , 2012, Future oncology.

[22]  Anish Thomas,et al.  Immunotherapies for non-small-cell lung cancer and mesothelioma. , 2012, The Lancet. Oncology.

[23]  L. Langman,et al.  The challenges of personalized medicine. , 2012, Clinical biochemistry.

[24]  P. Hohenstein,et al.  WT1 in disease: shifting the epithelial–mesenchymal balance , 2012, The Journal of pathology.

[25]  M. Ladomery,et al.  WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. , 2011, Cancer cell.

[26]  L. Pusztai,et al.  Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.

[27]  D. Loeb,et al.  WT1 Protein Directly Regulates Expression of Vascular Endothelial Growth Factor and Is a Mediator of Tumor Response to Hypoxia* , 2011, The Journal of Biological Chemistry.

[28]  Holger Gerhardt,et al.  Basic and Therapeutic Aspects of Angiogenesis , 2011, Cell.

[29]  H. Scholz,et al.  Wilms’ tumour protein Wt1 stimulates transcription of the gene encoding vascular endothelial cadherin , 2010, Pflügers Archiv - European Journal of Physiology.

[30]  G. Soma,et al.  WT1 expression correlates with angiogenesis in endometrial cancer tissue. , 2010, Anticancer research.

[31]  J. Wolchok,et al.  Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. , 2010, Blood.

[32]  Abdelkader Essafi,et al.  Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin , 2009, Nature Genetics.

[33]  Martin A. Cheever,et al.  The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.

[34]  C. Sotiriou,et al.  Development and Validation of Gene Expression Profile Signatures in Early-Stage Breast Cancer , 2009, Cancer investigation.

[35]  P. Neven,et al.  Wilms' tumor gene 1 (WT1) in endometrial carcinoma. , 2008, Gynecologic oncology.

[36]  M. Minden,et al.  Wilms' Tumor 1 Suppressor Gene Mediates Antiestrogen Resistance via Down-Regulation of Estrogen Receptor-α Expression in Breast Cancer Cells , 2008, Molecular Cancer Research.

[37]  Zhaoyi Wang,et al.  The Wilms' tumor suppressor WT1 inhibits malignant progression of neoplastigenic mammary epithelial cells. , 2008, Anticancer research.

[38]  K. Wagner,et al.  The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo , 2008, Oncogene.

[39]  Y. Hiasa,et al.  Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis. , 2008, European journal of cancer.

[40]  I. Weissman,et al.  The Wilms’ tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis , 2007, Leukemia.

[41]  D. Loeb,et al.  Isoforms of Wilms’ tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells , 2007, Oncogene.

[42]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[43]  I. Kawase,et al.  Immunohistochemical detection of WT1 protein in a variety of cancer cells , 2006, Modern Pathology.

[44]  M. Wilkinson,et al.  Tissue-specific RNAi reveals that WT1 expression in nurse cells controls germ cell survival and spermatogenesis. , 2006, Genes & development.

[45]  C. Axelsson,et al.  The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG) , 2004, Breast Cancer Research and Treatment.

[46]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  K. Wagner,et al.  The Wilms' tumor suppressor Wt1 is expressed in the coronary vasculature after myocardial infarction , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  Y. Miyoshi,et al.  High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  C. Yue,et al.  Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene , 2001, Oncogene.

[50]  C. B. Patel,et al.  Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. , 2001, Cancer research.

[51]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[52]  R. Cardiff,et al.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[53]  C. Roberts,et al.  Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Green,et al.  Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[55]  H. Pass,et al.  Wilms' tumor suppressor gene expression in rat and human mesothelioma. , 1994, Cancer research.

[56]  J. Bard,et al.  The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo , 1993, Mechanisms of Development.

[57]  D. Housman,et al.  Expression of the Wilms' tumor gene WT1 in the murine urogenital system. , 1991, Genes & development.

[58]  S Marsoni,et al.  The phase II trial. , 1985, Cancer treatment reports.

[59]  R. Blamey,et al.  A prognostic index in primary breast cancer. , 1982, British Journal of Cancer.